Article
Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Experimental and molecular pathology - 1 Dec 2008
Rickard Steve, Ono Santa Jeremy
Abstract excerpt
A promising cancer treatment strategy involves stimulation of anti-tumor immune responses. CD4(+) T cell responses are particularly desirable, as they enhance CD8(+) T cell activity and provide immune memory. The major histocompatibility complex (MHC) class II transactivator CIITA can be used to stimulate expression of MHC II on tumor cells, thereby promoting CD4(+) T cell activation. In this study, N2a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.